JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.

ABSTRACT: Gastric cancer is the third most common malignancy in China, with a median 5-year survival of only 20%. Cisplatin has been used in first-line cancer treatment for several types of cancer including gastric cancer. However, patients are often primary resistant or develop acquired resistance resulting in relapse of the cancer and reduced survival. Recently, we demonstrated that the reduced expression of base excision repair protein XRCC1 and its upstream regulator JWA in gastric cancerous tissues correlated with a significant survival benefit of adjuvant first-line platinum-based chemotherapy as well as XRCC1 playing an important role in the DNA repair of cisplatin-resistant gastric cancer cells. In the present study, we demonstrated the role of JWA in cisplatin-induced DNA lesions and aquire

SUBMITTER: Xu W 

PROVIDER: S-EPMC4649833 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature